RPL554 Provides Extra Dilation and Could Help People with COPD

Verona Pharma plc. a U.K.-based clinical stage pharmaceutical company, recently announced positive results from a phase 2 clinical trial testing their compound RPL554. According to the company, the therapy provides extra dilation of the passageways into the lungs in patients with chronic obstructive pulmonary disease (COPD) used in combination with standard medicines…